海泰新光(688677) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached RMB 602.61 million, a year-on-year increase of 36.08%[2] - Net profit attributable to shareholders was RMB 171.60 million, reflecting a growth of 26.79% compared to the previous year[2] - The net profit excluding non-recurring gains and losses was RMB 166.15 million, up 28.67% year-on-year[2] - Basic earnings per share increased to RMB 1.44, representing a growth of 28.57%[2] - Total assets at the end of the reporting period were RMB 1,635.11 million, an increase of 11.99% from the beginning of the period[2] - Shareholders' equity attributable to the parent company was RMB 1,347.90 million, up 3.41%[2] Business Growth - The company’s medical endoscope and optical business segments experienced significant growth, contributing to overall revenue increase[6] - The overall operating performance remains stable, with significant revenue growth driven by strategic adjustments and product development[5] Strategic Initiatives - The company has increased investment in R&D and market efforts for its proprietary brand products, laying a foundation for future growth[5] - The company has adapted to U.S. tariffs by shifting production to domestic and overseas factories, mitigating tariff impacts[5]